Novo Nordisk

Photo shows Novo Nordisk logo on building/Courtesy joreks/Getty Images Novo Nordisk and Dewpoint Therapeutics have inked a deal to use the latter's biomolecular condensates discovery platform to treat insulin resistance and diabetic complications. The deal couples Novo Nordisk's experience in diabetes with Dewpoint’s discovery and artificial intelligence (AI) platform. The companies will work to discover potential…

First biomolecular condensates research collaboration to identify drug candidates related to insulin resistance and diabetic complications Dewpoint is eligible to receive up to $55 million near term and up to $690 million of clinical, commercial and sales milestones plus royalties across two commercial products BOSTON , March 22, 2023 /PRNewswire/…

Researchers in the UK have developed StarCrete, a durable new building material designed for use on Mars. The primary ingredient? Potato starch. We’d be interested in touring the testing facility for… reasons. In today’s email: Weight loss injections: Why they’re here to stay. The “jock tax” is not just for athletes. Adobe: Of course it’s…

Pharmaceutical giant Novo Nordisk has recently announced a strategic partnership with Microsoft to enhance drug discovery and development using artificial intelligence (AI) models. This mutually-beneficial collaboration will enable Novo Nordisk to accelerate its research and development efforts, and Microsoft will be able to improve the sophistication of its AI technology. Taking a “platform approach”, the…

New AI models will summarize scientific research and predict the likelihood of atherosclerosis

Through the partnership, Microsoft is providing AI technology, foundational science models and expertise and is working alongside Novo Nordisk’s data scientists and domain experts from early research and development areas to accelerate Novo Nordisk’s R&D. A spokesperson for the Danish diabetes giant told BioPharma-Reporter: “The collaboration with Microsoft focuses on early research and drug development…

Novo Nordisk and Microsoft will adopt a platform strategy to AI under the deal to train several models for various tasks. Credit: Novo Nordisk A/S. …

Microsoft (MSFT) and Novo Nordisk (NVO) are undertaking a multi-year collaboration to combine the tech giant's computational cloud and artificial intelligence ((AI)) services with...

Novo Nordisk and Microsoft have announced a new strategic collaboration combining Microsoft’s computational services, cloud, and artificial intelligence (AI) with Novo Nordisk’s drug discovery, development, and data science capabilities. Through the partnership, Microsoft will provide its AI technology, foundational science models, and expertise to Novo Nordisks data scientists and domain experts for early research and…

Danish diabetes giant Novo Nordisk (NOV: N) and tech behemoth Microsoft (Nasdaq: MSFT) have entered a new multi-year strategic collaboration. The tie-up—the latest to bring together big pharma and big tech - combines Microsoft’s computational services, cloud and artificial intelligence (AI) with Novo Nordisk’s drug discovery, development and…

Artificial intelligence has increasingly become a go-to tool—rather than a novelty—for drugmakers looking to build the next generation of groundbreaking therapeutics. | Artificial intelligence has increasingly become a go-to tool—rather than a novelty—for drugmakers looking to build the next generation of groundbreaking therapeutics.

Bagsværd, Denmark and Redmond, WA, US, 12 September 2022 – Novo Nordisk and Microsoft have entered a new strategic collaboration to combine Microsoft’s computational services, cloud and artificial intelligence (AI) with Novo Nordisk’s drug discovery, development and data science capabilities. Through the partnership, Microsoft is providing AI technology, foundational science models and…